Effect of Berberine Hydrochloride on Blood Pressure and Vascular Endothelial Function in Patients With Hypertension
Status:
Recruiting
Trial end date:
2022-05-22
Target enrollment:
Participant gender:
Summary
Hypertension is a progressive cardiovascular syndrome caused by multiple causes, which can
lead to changes in the function and structure of the heart and blood vessels. It is the
leading risk factor of cardiovascular disease.
Berberine (BBR) hydrochloride is an isoquinoline alkaloid (chemical formula: C20H18NO4)
extracted from traditional Chinese herb Coptis chinensis. It has been widely used to treat
diarrhea and enteritis for hundreds of years in China. BBR has extremely high clinical
application value. It is an over-the-counter drug with low price, good safety and few adverse
reactions in China.
We found that Berberine (BBR) hydrochloride tablets have a hypotensive effect in clinical
practice. However, there are few clinical studies on the treatment of hypertensive patients
with BBR tablets. In addition, the clinical dosage of BBR tablets is not uniform, and its
molecular mechanism is still unclear.
In order to further evaluate the clinical efficacy of BBR in reducing blood pressure and
improving vascular endothelial injury, we carried out this clinical trial of drug
intervention for hypertensive population.
After signed the informed consent, the subjects are assigned to the lifestyle intervention
group (CON) and berberine hydrochloride group (BBR). The berberine hydrochloride group (BBR)
take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months) . We will follow up blood
pressure and vascular endothelial function in 1 month and 3 months after taking the medicine.